Pulmonary vasculitis in the intensive care unit

Journal of Intensive Care Medicine

Volumn 26, Issue 2, 2011, Pages 88-104

  Diaz, Jesus ^a   Calamia, Kenneth T ^a   Lee, Augustine S ^a  

^a MAYO CLINIC   (United States)

Author keywords

diffuse alveolar hemorrhage; intensive care unit; pulmonary capillaritis; pulmonary vasculitis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MESNA; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CRITICALLY ILL PATIENT; DIAGNOSTIC PROCEDURE; DIFFUSE ALVEOLAR HEMORRHAGE; DISEASE ACTIVITY; DRUG EFFICACY; HEMOPTYSIS; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LABORATORY TEST; LEUKOPENIA; LUNG HEMORRHAGE; PLASMAPHERESIS; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY VASCULITIS; RESPIRATORY DISTRESS SYNDROME; REVIEW;

HUMANS; INTENSIVE CARE; LUNG DISEASES; RISK FACTORS; VASCULITIS;

EID: 79953884599     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066610384551     Document Type: Review

References (88)

1. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337(21):1512-1523. (Pubitemid 27495778)
2. Khan SA, Subla MR, Behl D, Specks U, Afessa B. Outcome of patients with small-vessel vasculitis admitted to a medical ICU. Chest. 2007;131(4):972-976. (Pubitemid 46608694)
3. Cruz BA, Ramanoelina J, Mahr A, et al. Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology (Oxford). 2003;42(10):1183-1188. (Pubitemid 37258481)
4. National Institute of Allergy and Infectious Diseases (U.S.). Autoimmune Diseases Coordinating Committee. Progress in Autoimmune Diseases Research-Report to Congress. Bethesda, MD: National Institutes of Health; 2005.
5. Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7(4):270-275.
6. Godeau B, Mortier E, Roy PM, et al. Short and longterm outcomes for patients with systemic rheumatic diseases admitted to intensive care units: a prognostic study of 181 patients. J Rheumatol. 1997;24(7):1317-1323. (Pubitemid 27353375)
7. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin. 2002;18(4):729-748. (Pubitemid 35215558)
8. Kollef MH, Enzenauer RJ. Predicting outcome from intensive care for patients with rheumatologic diseases. J Rheumatol. 1992;19(8):1260-1262.
9. Moreels M, Melot C, Leeman M. Prognosis of patients with systemic rheumatic diseases admitted to the intensive care unit. Intensive Care Med. 2005;31(4):591-593. (Pubitemid 40543893)
10. Bouachour G, Roy PM, Tirot P, Guerin O, Gouello JP, Alquier P. Prognosis of systemic diseases diagnosed in intensive care units. Presse Med. 1996;25(18):837-841. (Pubitemid 26184794)
11. Patel SR, Karmpaliotis D, Ayas NT, et al. The role of open-lung biopsy in ARDS. Chest. Jan 2004;125(1):197-202. (Pubitemid 38120270)
12. Baumann HJ, Kluge S, Balke L, et al. Yield and safety of bedside open lung biopsy in mechanically ventilated patients with acute lung injury or acute respiratory distress syndrome. Surgery. 2008;143(3):426-433. (Pubitemid 351248924)
13. Kramer MR, Berkman N, Mintz B, Godfrey S, Saute M, Amir G. The role of open lung biopsy in the management and outcome of patients with diffuse lung disease. Ann Thorac Surg. 1998;65(1):198-202. (Pubitemid 28105892)
14. Papazian L, Thomas P, Bregeon F, et al. Open-lung biopsy in patients with acute respiratory distress syndrome. Anesthesiology. 1998;88(4):935-944. (Pubitemid 28193320)
15. Esteban A, Fernandez-Segoviano P, Frutos-Vivar F, et al. Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings. Ann Intern Med. 2004;141(6):440-445.
16. de Hemptinne Q, Remmelink M, Brimioulle S, Salmon I, Vincent JL. ARDS: a clinicopathological confrontation. Chest. 2009;135(4):944-949.
17. Papazian L, Doddoli C, Chetaille B, et al. A contributive result of open-lung biopsy improves survival in acute respiratory distress syndrome patients. Crit Care Med. 2007;35(3):755-762. (Pubitemid 46407787)
18. Seo P, Luqmani RA, Flossmann O, et al. The future of damage assessment in vasculitis. J Rheumatol. 2007;34(6):1357-1371. (Pubitemid 46898123)
19. Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005;52(7):2168-2178. (Pubitemid 40994340)
20. Silvester W, Bellomo R, Cole L. Epidemiology, management, and outcome of severe acute renal failure of critical illness in Australia. Crit Care Med. 2001;29(10):1910-1915. (Pubitemid 32980400)
21. Kerr KM, Auger WR, Fedullo PF, Channick RH, Yi ES, Moser KM. Large vessel pulmonary arteritis mimicking chronic thromboembolic disease. Am J Respir Crit Care Med. 1995;152(1):367-373.
22. Park JH. Conventional and CT angiographic diagnosis of Takayasu arteritis. Int J Cardiol. 1996;54(2):S165-S171.
23. Yamada I, Shibuya H, Matsubara O, et al. Pulmonary artery disease in Takayasu's arteritis: angiographic findings. AJR Am J Roentgenol. 1992;159(2):263-269.
24. Yamamoto S, Ogawa S, Kitano T, et al. Complete evaluation of the cardiovascular lesions in 24 patients with Takayasu's aortitis using four-image, intravenous digital subtraction angiography. Am Heart J. 1987;114(6):1426-1431. (Pubitemid 18009501)
25. Huong Dle T, Andreu MR, Duhaut P, Godeau P, Piette JC. Intra-alveolar haemorrhage in temporal arteritis. Ann Rheum Dis. 2003;62(2):189-190.
26. Schett G, Winkler S, Hollenstein U, et al. Obstruction of the pulmonary artery by granulomatous vasculitis: a clinical, morphological, and immunological analysis. Ann Rheum Dis. 2002;61(5):463-467. (Pubitemid 34496829)
27. Landrin I, Chassagne P, Bouaniche M, et al. Pulmonary artery thrombosis in giant cell arteritis. A new case and review of literature. Ann Med Interne (Paris). 1997;148(4):315-316.
28. Gur H, Rapman E, Ehrenfeld M, Sidi Y. Clinical manifestations of temporal arteritis: a report from Israel. J Rheumatol. Nov 1996;23(11):1927-1931. (Pubitemid 26376118)
29. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122(7):502-507.
30. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore). 2009;88(4):227-235.
31. Salvarani C, Giannini C, Miller DV, Hunder G. Giant cell arteritis: Involvement of intracranial arteries. Arthritis Rheum. 2006;55(6):985-989. (Pubitemid 44917477)
32. Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985;64(2):89-99.
33. Takahashi K, Honda M, Furuse M, Yanagisawa M, Saitoh K. CT findings of pulmonary parenchyma in Takayasu arteritis. J Comput Assist Tomogr. 1996;20(5):742-748. (Pubitemid 26303750)
34. Lupi E, Sanchez G, Horwitz S, Gutierrez E. Pulmonary artery involvement in Takayasu's arteritis. Chest. 1975;67(1):69-74.
35. Nick J, Tuder R, May R, Fisher J. Polyarteritis nodosa with pulmonary vasculitis. Am J Respir Crit Care Med. 1996;153(1):450-453. (Pubitemid 26026888)
36. Bonsib SM. Polyarteritis nodosa. Semin Diagn Pathol. 2001;18(1):14-23. (Pubitemid 32194911)
37. Voynow JA, Schanberg L, Sporn T, Kredich D. Pulmonary complications associated with Kawasaki disease. J Pediatr. 2002;140(6):786-787. (Pubitemid 34666706)
38. Palmer AL, Walker T, Smith JC. Acute respiratory distress syndrome in a child with Kawasaki disease. South Med J. 2005;98(10):1031-1033. (Pubitemid 41572208)
39. Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behcet's disease in the US: a population-based study. Arthritis Rheum. 2009;61(5):600-604.
40. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet disease. Curr Opin Rheumatol. 2005;17(1):1-8. (Pubitemid 40075641)
41. Stone JH. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 2003;48(8):2299-2309. (Pubitemid 36959212)
42. Merkel PA, Lo GH, Holbrook JT, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142(8):620-626. (Pubitemid 40529958)
43. Russell KA, Wiegert E, Schroeder DR, Homburger HA, Specks U. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol. 2002;103(2):196-203. (Pubitemid 34596988)
44. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med. 2007;120(7):643 e649-614.
45. Vassilopoulos D, Niles JL, Villa-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum. 2003;49(2):151-155. (Pubitemid 36418271)
46. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421-430. (Pubitemid 29136088)
47. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26-37.
48. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore). 1997;76(3):192-202.
49. Witte RJ, Gurney JW, Robbins RA, et al. Diffuse pulmonary alveolar hemorrhage after bone marrow transplantation: radiographic findings in 39 patients. AJR Am J Roentgenol. 1991;157(3):461-464.
50. Cortese G, Nicali R, Placido R, Gariazzo G, Anro P. Radiological aspects of diffuse alveolar haemorrhage. Radiol Med. 2008;113(1):16-28. (Pubitemid 351387212)
51. Epstein CE, Elidemir O, Colasurdo GN, Fan LL. Time course of hemosiderin production by alveolar macrophages in a murine model. Chest. 2001;120(6):2013-2020. (Pubitemid 34053468)
52. Sherman JM, Winnie G, Thomassen MJ, Abdul-Karim FW, Boat TF. Time course of hemosiderin production and clearance by human pulmonary macrophages. Chest. 1984;86(3):409-411. (Pubitemid 14027355)
53. Perez-Arellano JL, Losa Garcia JE, Garcia Macias MC, Gomez Gomez F, Jimenez Lopez A, de Castro S. Hemosiderin-laden macrophages in bronchoalveolar lavage fluid. Acta Cytol. 1992;36(1):26-30.
54. De Lassence A, Fleury-Feith J, Escudier E, Beaune J, Bernaudin JF, Cordonnier C. Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med. 1995;151(1):157-163.
55. Lee AS, Specks U. Pulmonary capillaritis. Semin Respir Crit Care Med. 2004;25(5):547-555. (Pubitemid 39518249)
56. Maldonado F, Parambil JG, Yi ES, Decker PA, Ryu JH. Hemosiderin-laden macrophages in the BAL fluid of patients with diffuse alveolar damage. Eur Respir J. 2009;33(6):1361-1366.
57. Wunderink RG, Woldenberg LS, Zeiss J, Day CM, Ciemins J, Lacher DA. The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia. Chest. 1992;101(2):458-463.
58. Csernok E, Holle J, Hellmich B, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford). 2004;43(2):174-180. (Pubitemid 38219671)
59. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004;9(2):190-196. (Pubitemid 38937391)
60. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44. (Pubitemid 36765101)
61. Daum TE, Specks U, Colby TV, et al. Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med. 1995;151(2 Pt 1):522-526.
62. Givens CD, Jr., Newman JH, McCurley TL. Diagnosis of Wegener's granulomatosis by transbronchial biopsy. Chest. 1985;88(5):794-796.
63. Schnabel A, Holl-Ulrich K, Dalhoff K, Reuter M, Gross WL. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J. 1997;10(12):2738-2743. (Pubitemid 28052780)
64. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310-317.
65. Langford CA. Small-vessel vasculitis: therapeutic management. Curr Rheumatol Rep. 2007;9(4):328-335. (Pubitemid 47262614)
66. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180-2188. (Pubitemid 47041083)
67. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033-1042. (Pubitemid 32488657)
68. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003; 42(6):1149-1153. (Pubitemid 37486757)
69. Yamaji K, Kim YJ, Tsuda H, Takasaki Y. Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroidresistant lupus nephritis. Ther Apher Dial. 2008;12(4):298-305.
70. Asherson RA. The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus. 1998;7(2):S55-S62.
71. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6(2):98-103. (Pubitemid 44816525)
72. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40(4):757-763.
73. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76-85. (Pubitemid 13217969)
74. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670-680.
75. Holguin F, Ramadan B, Gal AA, Roman J. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am J Med Sci. 2008;336(4):321-326.
76. Lorente L, Blot S, Rello J. Evidence on measures for the prevention of ventilator-associated pneumonia. Eur Respir J. 2007;30(6):1193-1207. (Pubitemid 351194769)
77. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective- ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338(6):347-354. (Pubitemid 28083906)
78. Hayes-Bradley C. Hypoxia from vasculitic pulmonary haemorrhage improved by prone position ventilation. Br J Anaesth. 2004;92(5):754-757. (Pubitemid 38578769)
79. Hilbert G, Gruson D, Vargas F, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med. 2001;344(7):481-487. (Pubitemid 32164899)
80. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283- 1297.
81. Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest. 2007;131(5):1308-1314. (Pubitemid 46762333)
82. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173(2):180-187. (Pubitemid 43187890)
83. Stone JH MP, Seo P, Spiera R, et al. Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE) 73rd Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals October 18, 2009:Abstract #550.
84. Yildirim H, Ucgun I, Yalcin AU, et al. Recombinant factor VIIa treatment for life-threatening haemoptysis. Respirology. 2006;11(5):652-654. (Pubitemid 44186275)
85. Pastores SM, Papadopoulos E, Voigt L, Halpern NA. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest. 2003;124(6):2400-2403. (Pubitemid 38010618)
86. Nadir Y, Brenner B. Hemorrhagic and thrombotic complications in bone marrow transplant recipients. Thromb Res. 2007;120(2):S92-S98. (Pubitemid 350101777)
87. Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant. 2002;30(12):975-978. (Pubitemid 36097490)
88. Heslet L, Nielsen JD, Levi M, Sengelov H, Johansson PI. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Crit Care. 2006;10(6):R177.